Virginia Litwin, Ph.D.
President-Elect
Virginia Litwin is a thought-leader in validation and standardization for flow cytometry. Bringing “Cytometry from Bench-to-Bedside” has been the focus of her professional activities since 1999 when she started working in translational medicine at Bristol-Myers Squibb.
She co-founded the Flow Cytometry Community within the American Association of Pharmaceutical Scientists (AAPS). She was a councilor for ICCS and the International Society for the Advancement of Cytometry (ISAC). She serves on the ICCS Advocacy Committee whose mission is to interface with regulatory agencies and has been an invited speaker at FDA/NIST on many occasions.
Virginia serves on the Clinical and Laboratory Standards Institute (CLSI) Expert Panel and is the chair of the Document Development Committees for H62 and H42. She is an Associate Editor for Cytometry Part B: Clinical Cytometry. She edited the book, Flow Cytometry in Drug Discovery and Development, as well as journal special issues: JIM- Flow Cytometry Biomarkers and Translational Medicine (2011); Cytometry Part B- Receptor Occupancy (2015); Cytometry Part B- Cytometry Advancing Next Generation Drug Development (2021).
Virginia is the 2023 recipient of the ICCS Wallace H. Coulter award in recognition of her contributions to the science, education and practice of Clinical Cytometry.
After obtaining a Ph.D. in Virology/Immunology from the University of Iowa, Virginia joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified the KIR receptor, KIR3DL1 (CD158E1). She has held leadership roles in several contract research organizations. Currently she is Scientific Affairs Director at Eurofins BioPharma Services.